Scan to Download ios&Android APP

Trade Exelixis, Inc. - EXEL CFD

20.98
0.19%
0.14
Low: 21.19
High: 21.95
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Exelixis Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

Key Stats
Prev. Close* 21.43
Open* 21.6
Day's Range* 21.19 - 21.19
1-Year Change* 25.22%
Volume N/A
Average Vol. (3m) 58.7766
52 wk Range N/A
Market Cap 6902.34
P/E Ratio 23.3213
Shares Outstanding 320741000
Revenue 1520.72
EPS 0.92276
Dividend (Yield %) N/A
Beta 0.60548
Next Earnings Date Aug 9, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 5, 2022 21.43 0.24 1.13% 21.19 21.67 20.93
Aug 4, 2022 21.37 0.16 0.75% 21.21 21.49 21.13
Aug 3, 2022 21.32 -0.07 -0.33% 21.39 21.91 21.31
Aug 2, 2022 21.42 0.59 2.83% 20.83 21.50 20.73
Aug 1, 2022 20.89 0.06 0.29% 20.83 21.05 20.69
Jul 29, 2022 20.87 -0.35 -1.65% 21.22 21.35 20.60
Jul 28, 2022 20.68 -0.43 -2.04% 21.11 21.14 20.27
Jul 27, 2022 21.20 0.03 0.14% 21.17 21.36 20.89
Jul 26, 2022 21.28 0.32 1.53% 20.96 21.64 20.96
Jul 25, 2022 20.96 0.10 0.48% 20.86 21.00 20.59
Jul 22, 2022 20.80 -0.54 -2.53% 21.34 21.35 20.68
Jul 21, 2022 21.32 -0.47 -2.16% 21.79 21.79 21.21
Jul 20, 2022 21.87 0.16 0.74% 21.71 22.08 21.62
Jul 19, 2022 21.79 0.16 0.74% 21.63 21.88 21.41
Jul 18, 2022 21.52 0.38 1.80% 21.14 22.05 21.14
Jul 15, 2022 21.28 0.07 0.33% 21.21 21.33 20.96
Jul 14, 2022 21.25 -0.09 -0.42% 21.34 21.45 21.02
Jul 13, 2022 21.55 0.89 4.31% 20.66 21.78 20.54
Jul 12, 2022 20.99 0.35 1.70% 20.64 21.21 20.37
Jul 11, 2022 20.57 -1.07 -4.94% 21.64 21.76 20.38

Exelixis, Inc. Events

Time (UTC) Country Event
Monday, October 31, 2022
10:59
  US
Q3 2022 Exelixis Inc Earnings Release
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 191.454 452.477 853.826 967.775 987.538 1434.97
Revenue 191.454 452.477 853.826 967.775 987.538 1434.97
Cost of Revenue, Total 6.552 15.066 26.348 33.097 36.272 52.873
Gross Profit 184.902 437.411 827.478 934.678 951.266 1382.1
Total Operating Expense 233.479 290.104 414.971 598.305 877.478 1148.3
Selling/General/Admin. Expenses, Total 116.145 159.362 206.366 228.244 293.355 401.715
Research & Development 95.967 112.171 182.257 336.964 547.851 693.716
Unusual Expense (Income) 14.815 3.505 0
Operating Income -42.025 162.373 438.855 369.47 110.06 286.666
Interest Income (Expense), Net Non-Operating -28.197 -3.796 12.84 27.959 19.865 7.672
Net Income Before Taxes -70.222 158.577 452.092 398.109 130.837 294.154
Net Income After Taxes -70.222 154.227 690.07 321.012 111.781 231.063
Net Income Before Extra. Items -70.222 154.227 690.07 321.012 111.781 231.063
Net Income -70.222 154.227 690.07 321.012 111.781 231.063
Income Available to Common Excl. Extra. Items -70.222 154.227 690.07 321.012 111.781 231.063
Income Available to Common Incl. Extra. Items -70.222 154.227 690.07 321.012 111.781 231.063
Diluted Net Income -70.222 154.227 690.07 321.012 111.781 231.063
Diluted Weighted Average Shares 250.531 312.003 312.803 315.009 318.001 322.359
Diluted EPS Excluding Extraordinary Items -0.28029 0.49431 2.20608 1.01906 0.35151 0.71679
Diluted Normalized EPS -0.22116 0.50524 2.20608 1.01906 0.35151 0.71679
Total Extraordinary Items 0
Dilution Adjustment 0 0
Other, Net 0.397 0.68 0.912 -0.184
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 270.23 385.177 328.423 451.14 355.98
Revenue 270.23 385.177 328.423 451.14 355.98
Cost of Revenue, Total 13.198 14.884 11.874 12.917 13.203
Gross Profit 257.032 370.293 316.549 438.223 342.777
Total Operating Expense 274.837 262.169 276.802 334.496 272.737
Selling/General/Admin. Expenses, Total 102.351 98.495 101.558 99.311 102.863
Research & Development 159.288 148.79 163.37 222.268 156.671
Operating Income -4.607 123.008 51.621 116.644 83.243
Interest Income (Expense), Net Non-Operating 2.682 1.891 1.658 1.441 1.822
Other, Net -0.09 -0.011 -0.019 -0.064 0.164
Net Income Before Taxes -2.015 124.888 53.26 118.021 85.229
Net Income After Taxes 1.601 96.092 38.204 95.166 68.573
Net Income Before Extra. Items 1.601 96.092 38.204 95.166 68.573
Net Income 1.601 96.092 38.204 95.166 68.573
Income Available to Common Excl. Extra. Items 1.601 96.092 38.204 95.166 68.573
Income Available to Common Incl. Extra. Items 1.601 96.092 38.204 95.166 68.573
Diluted Net Income 1.601 96.092 38.204 95.166 68.573
Diluted Weighted Average Shares 321.287 322.941 322.022 323.184 323.289
Diluted EPS Excluding Extraordinary Items 0.00498 0.29755 0.11864 0.29446 0.21211
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS 0.00498 0.29755 0.11864 0.29446 0.21211
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 469.001 484.874 897.016 1011.19 1445.4 1834.75
Cash and Short Term Investments 419.803 387.771 693.334 852.243 1206.54 1467.07
Cash & Equivalents 151.686 183.164 314.775 266.501 319.217 647.169
Short Term Investments 268.117 204.607 378.559 585.742 887.319 819.905
Total Receivables, Net 40.444 81.192 178.827 120.173 160.875 282.65
Accounts Receivable - Trade, Net 40.444 77.3 162.771 120.173 160.875 282.65
Total Inventory 3.338 6.657 9.838 12.886 20.973 27.493
Prepaid Expenses 5.416 8.75 15.017 25.888 57.011 57.53
Total Assets 595.739 655.294 1422.29 1885.67 2137.33 2616.24
Property/Plant/Equipment, Total - Net 2.071 25.743 56.764 90.727 110.394 149.153
Goodwill, Net 63.684 63.684 63.684 63.684 63.684 63.684
Long Term Investments 55.601 64.255 157.187 534.749 332.306 371.112
Other Long Term Assets, Total 5.382 16.738 247.635 185.32 185.554 195.878
Total Current Liabilities 268.786 115.17 105.472 142.746 204.658 337.59
Accounts Payable 6.565 9.575 10.901 11.581 23.632 24.258
Accrued Expenses 53.434 66.046 60.53 90.725 115.896 231.403
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 189.122 0 0.049
Other Current Liabilities, Total 19.665 39.549 33.992 40.44 65.13 81.929
Total Liabilities 506.421 370.333 134.833 199.7 258.22 405.624
Total Long Term Debt 0 14.53 0.079 0 0 0
Other Liabilities, Total 237.635 240.633 29.282 56.954 53.562 68.034
Total Equity 89.318 284.961 1287.45 1685.97 1879.11 2210.61
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.29 0.296 0.3 0.305 0.312 0.319
Additional Paid-In Capital 2072.59 2114.18 2168.22 2241.95 2321.9 2427.56
Retained Earnings (Accumulated Deficit) -1983.15 -1829.17 -880.363 -559.351 -447.57 -216.507
Other Equity, Total -0.416 -0.347 -0.701 3.069 4.476 -0.758
Total Liabilities & Shareholders’ Equity 595.739 655.294 1422.29 1885.67 2137.33 2616.24
Total Common Shares Outstanding 289.924 296.209 299.876 304.831 311.627 318.842
Other Current Assets, Total 0.504 0
Capital Lease Obligations 14.53 0.079
Property/Plant/Equipment, Total - Gross 74.073 116.287 145.078 189.984
Accumulated Depreciation, Total -17.309 -25.56 -34.684 -40.831
Note Receivable - Long Term 1.665
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 1434.27 1593.25 1662.03 1834.75 1842.74
Cash and Short Term Investments 1185.49 1346.63 1402.73 1467.07 1570.33
Cash & Equivalents 370.209 492.462 567.325 647.169 723.269
Short Term Investments 815.285 854.171 835.406 819.905 847.06
Total Receivables, Net 177.673 181.502 179.493 282.65 190.614
Accounts Receivable - Trade, Net 177.673 181.502 179.493 282.65 190.614
Total Inventory 24.757 24.982 28.24 27.493 28.467
Prepaid Expenses 46.341 40.129 51.564 57.53 53.333
Total Assets 2190.54 2367.27 2447.74 2616.24 2654.12
Property/Plant/Equipment, Total - Net 78.453 95.133 99.838 104.031 106.169
Goodwill, Net 63.684 63.684 63.684 63.684 63.684
Long Term Investments 279.148 298.774 331.055 371.112 404.535
Other Long Term Assets, Total 334.992 315.486 281.692 241 233.752
Total Current Liabilities 213.337 255.326 269.508 337.59 289.079
Accounts Payable 13.821 20.45 24.314 24.258 17.285
Accrued Expenses 111.168 139.827 159.327 226.266 158.145
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 88.348 95.049 85.867 87.066 113.649
Total Liabilities 279.355 324.194 335.294 405.624 360.267
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 66.018 68.868 65.786 68.034 71.188
Total Equity 1911.19 2043.08 2112.45 2210.61 2293.85
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.313 0.315 0.316 0.319 0.32
Additional Paid-In Capital 2354.1 2390.65 2422.32 2427.56 2448.13
Retained Earnings (Accumulated Deficit) -445.969 -349.877 -311.673 -216.507 -147.934
Other Equity, Total 2.74 1.985 1.481 -0.758 -6.665
Total Liabilities & Shareholders’ Equity 2190.54 2367.27 2447.74 2616.24 2654.12
Total Common Shares Outstanding 313.262 314.822 316.305 318.842 320.268
Note Receivable - Long Term 0.948 9.444 1.665 3.235
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -70.222 154.227 690.07 321.012 111.781 231.063
Cash From Operating Activities 210.404 165.611 415.72 526.956 208.982 400.804
Cash From Operating Activities 1.002 1.187 4.915 8.348 9.141 13.63
Deferred Taxes 0 0 -244.111 71.002 15.265 46.529
Non-Cash Items 44.349 28.968 44.609 59.509 112.935 148.595
Cash Taxes Paid 0.19 0.538 10.677 7.873 4.115 12.96
Cash Interest Paid 21.044 20.46 0 0
Changes in Working Capital 235.275 -18.771 -79.763 67.085 -40.14 -39.013
Cash From Investing Activities -214.548 36.795 -297.85 -587.247 -131.215 -42.884
Capital Expenditures -1.703 -21.143 -33.297 -12.834 -30.345 -64.225
Other Investing Cash Flow Items, Total -212.845 57.938 -264.553 -574.413 -100.87 21.341
Cash From Financing Activities 15.696 -169.928 9.691 12.553 -25.132 -14.801
Financing Cash Flow Items -4.108 -6.563 -7.574 -9.946 -50.018 -39.108
Issuance (Retirement) of Stock, Net 27.514 22.423 17.278 22.499 24.886 24.307
Issuance (Retirement) of Debt, Net -7.71 -185.788 -0.013 0
Net Change in Cash 11.552 32.478 127.561 -47.738 52.635 343.119
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 1.601 97.693 135.897 231.063 68.573
Cash From Operating Activities 39.544 221.045 304.352 400.804 147.719
Cash From Operating Activities 3.227 6.895 11.699 13.63 4.49
Deferred Taxes -3.388 22.8 32.365 46.529 15.318
Non-Cash Items 42.452 88.105 136.477 148.595 22.724
Changes in Working Capital -4.348 5.552 -12.086 -39.013 36.614
Cash From Investing Activities 62.255 -8.59 -29.829 -42.884 -74.539
Capital Expenditures -13.557 -33.768 -48.265 -64.225 -5.609
Other Investing Cash Flow Items, Total 75.812 25.178 18.436 21.341 -68.93
Cash From Financing Activities -2.65 6.074 3.193 -14.801 0.205
Financing Cash Flow Items -5.441 -9.413 -15.049 -39.108 -4.686
Issuance (Retirement) of Stock, Net 2.791 15.487 18.242 24.307 4.891
Net Change in Cash 99.149 218.529 277.716 343.119 73.385

Still looking for a broker you can trust?

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Exelixis Company profile

Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry: Bio Therapeutic Drugs

1851 Harbor Bay Parkway
ALAMEDA
CALIFORNIA 94502
US

Income statement

People Also Watch

Ripple to US Dollar

0.37 Price
+1.220% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 0.00600

Market analysis

Exelixis, Inc. (EXEL) is up 1.27% on Friday: What You Should Know

Exelixis, Inc. (EXEL) stock is up 1.27% in the last day. For details on what happened in the market, see our analysis.

07:00, 8 August 2022

Learn more about

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading